[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch1][C][C][Branch1][=Branch1][C][=Branch1][C][=O][O][O][/N][=C][Branch1][O][/C][=N][S][C][=Branch1][Ring2][=N][Ring1][Branch1][N][\\C][=Branch1][C][=O][N][C@H1][C@@H1][N][Branch1][Branch1][C][Ring1][Ring2][=O][C][=Branch2][Ring1][#C][=C][Branch1][Branch1][C][S][Ring1][Branch2][C][N+1][=C][C][=Branch1][=Branch2][=C][Branch1][Branch1][N][Ring1][Branch1][C][N][N][C][=Branch1][C][=O][N][C][C][N][C][=Branch1][C][=O][O-1]"}, {"from": "gpt", "value": "The molecule is a semi-synthetic broad-spectrum fifth generation cephalosporin. It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections. The manufacturer of this drug is Cubist Pharmaceuticals. Most recently, in June 2019, ceftolozane-tazobactam was approved for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.  Hospital-acquired pneumonia and ventilator-associated pneumonia are major causes of morbidity and mortality in hospitalized patients and the use of ceftolozane-tazobactam offers effective activity against various organisms causing these infections, such as Pseudomonas aeruginosa."}]